Praluent vs Leqvio Cost and Access Head-to-Head: Alirocumab vs Inclisiran

What Are Praluent and Leqvio, and How Do They Differ?

Praluent (alirocumab) is a fully human monoclonal antibody that binds free circulating PCSK9 protein, preventing it from degrading LDL receptors on hepatocytes. Leqvio (inclisiran) is a small-interfering RNA (siRNA) that targets PCSK9 messenger RNA inside liver cells, reducing PCSK9 synthesis at the source. Both drugs ultimately increase LDL receptor recycling and lower plasma LDL-C by roughly 50%, but the molecular strategy is completely different.

Alirocumab: How It Works

Alirocumab binds extracellular PCSK9 directly. Because the protein is neutralized before it reaches the LDL receptor, the effect wears off as new PCSK9 protein is synthesized, requiring dosing every 14 days [1]. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering [2].

Inclisiran: How It Works

Inclisiran conjugated to GalNAc (N-acetylgalactosamine) is taken up by asialoglycoprotein receptors on hepatocytes and cleaved intracellularly into active siRNA. That siRNA silences PCSK9 mRNA transcription. Because the gene-silencing effect persists inside the cell, the drug needs only maintenance injections every six months after the loading phase [3]. The FDA approved inclisiran in December 2021 [4].

Why the Mechanism Gap Matters Clinically

The downstream LDL-C numbers look similar on paper. The practical differences appear in who administers the drug, how the patient's lifestyle intersects with adherence, and how payers classify and reimburse each agent. A 2022 analysis in the Journal of the American College of Cardiology estimated that non-adherence to biweekly PCSK9 antibody therapy results in real-world LDL-C control roughly 15-20% lower than trial figures [5].

LDL-C Efficacy: Comparing the Trial Data

Neither drug has been tested head-to-head in a randomized trial. The comparison below draws on the best available phase 3 evidence for each agent individually.

ODYSSEY OUTCOMES: Alirocumab's Landmark Trial

ODYSSEY OUTCOMES enrolled 18,924 patients with acute coronary syndrome within the prior 1 to 12 months, all on high-intensity or maximum-tolerated statin therapy [6]. Alirocumab 75 mg every 2 weeks (titrated to 150 mg if LDL-C remained above 50 mg/dL) produced a mean LDL-C reduction of 54.7% from baseline at 48 weeks compared with placebo [6]. More clinically relevant: alirocumab reduced the composite primary MACE endpoint (coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) by 15% relative risk reduction (HR 0.85, 95% CI 0.78-0.93, P<0.001) over a median follow-up of 2.8 years [6].

The absolute risk reduction was 1.6 percentage points (11.1% alirocumab vs 12.7% placebo), translating to a number needed to treat of 63 over 2.8 years [6]. Patients with baseline LDL-C at or above 100 mg/dL showed an absolute risk reduction of 2.4 percentage points, suggesting greater benefit in higher-risk, higher-LDL subgroups [6].

ORION-10 and ORION-11: Inclisiran's Phase 3 Evidence

ORION-10 (N=1,561, primary prevention high-risk patients) and ORION-11 (N=1,617, ASCVD or ASCVD risk equivalents) both reported their 18-month results in the same 2020 NEJM publication [7]. Inclisiran 284 mg at Day 1, Day 90, and every 6 months thereafter produced a time-averaged LDL-C reduction of 51% in ORION-10 and 49% in ORION-11 compared with placebo [7]. Critically, reductions were sustained between injections, with trough LDL-C at month 17 still 52% below baseline in ORION-10 [7].

ORION-10 and ORION-11 were not powered for MACE outcomes. The cardiovascular outcomes trial for inclisiran, ORION-4 (N=15,000+, estimated completion 2026), is ongoing. Prescribers and patients choosing inclisiran today are accepting the absence of hard MACE-reduction data [8].

Head-to-Head Summary Table

| Feature | Alirocumab (Praluent) | Inclisiran (Leqvio) | |---|---|---| | LDL-C reduction | ~54-60% | ~49-52% | | MACE outcome data | Yes (ODYSSEY OUTCOMES, HR 0.85) | No (ORION-4 pending) | | Dosing frequency | Every 14 days | 2x per year (after loading) | | Administration | Patient self-injection | Clinician-administered | | FDA approval year | 2015 | 2021 |

Cardiovascular Outcomes: Where the Evidence Asymmetry Sits

Alirocumab has Level A evidence for MACE reduction in post-ACS patients. Inclisiran does not yet have that evidence. The 2022 ACC/AHA Guideline on the Management of Patients with Chronic Coronary Disease states that PCSK9 inhibitors with proven outcomes data receive a Class IIa, Level A recommendation for very-high-risk patients not at LDL-C goal on maximally tolerated statins plus ezetimibe [9].

What Guidelines Say About Inclisiran

The ACC Expert Consensus Decision Pathway published in 2022 specifically notes that inclisiran represents "an additional therapeutic option for LDL-C lowering in high-risk patients, particularly where adherence to frequent injections is a concern," but acknowledges that outcomes data remain pending [10]. The European Society of Cardiology 2021 guidelines similarly include inclisiran as a third-line option after statins and ezetimibe, with the caveat that hard endpoint trials are awaited [11].

Practical Implications

For a patient who had a heart attack six months ago and whose LDL-C is 95 mg/dL on rosuvastatin 40 mg plus ezetimibe 10 mg, the ODYSSEY OUTCOMES data give alirocumab a direct evidence claim that inclisiran cannot yet make. Cardiologists at high-volume centers frequently use this distinction when documenting medical necessity for prior authorization.

Cost and List Price: Breaking Down the Numbers

Both drugs carry list prices that place them far outside out-of-pocket reach for most patients without insurance coverage.

Alirocumab (Praluent) Pricing

Sanofi's U.S. List price for alirocumab is approximately $578-$628 per 2-week prefilled pen, translating to roughly $15,000 per year at list. However, Sanofi operates a patient access program and has negotiated significantly lower net prices with pharmacy benefit managers. As of 2024, the effective average net price after rebates is estimated at $5,800-$6,600 per year for commercially insured patients [12]. The Sanofi Insulins VAL-U program and manufacturer co-pay cards can reduce patient out-of-pocket costs to as low as $0/month for eligible commercially insured patients [13].

Inclisiran (Leqvio) Pricing

Novartis lists inclisiran at approximately $3,250 per injection. With two maintenance injections per year (after the Day 1 and Day 90 loading doses), that amounts to roughly $6,500 per year at list for established patients. Because inclisiran is a physician-administered drug (buy-and-bill model), it bills under the medical benefit rather than the pharmacy benefit. This distinction is significant: Medicare Part B covers physician-administered drugs, potentially making inclisiran more accessible for Medicare patients who face high Part D cost-sharing for self-injected biologics [14].

Novartis offers the Leqvio CONNECT patient support program, which provides co-pay assistance for eligible commercially insured patients [15].

The Medical Benefit vs. Pharmacy Benefit Divide

This single structural difference may matter more than the list price gap for some patients. Alirocumab, self-injected at home, typically routes through Part D (pharmacy benefit), which carries a deductible and a catastrophic cost-sharing phase. Inclisiran, given in a physician's office or infusion center, routes through Part B (medical benefit) at an 80/20 coinsurance after the Part B deductible, with no separate drug deductible [14]. For a Medicare patient with a Medigap supplemental policy covering Part B coinsurance, inclisiran could have near-zero out-of-pocket cost. A 2023 analysis in Circulation: Cardiovascular Quality and Outcomes modeled this scenario and found inclisiran may produce lower total out-of-pocket costs for Medicare patients than alirocumab, despite similar annual list prices [16].

Insurance Coverage and Prior Authorization

Prior authorization (PA) is the dominant access barrier for both drugs. Both are PCSK9 inhibitors and face similar PA hurdles, but the pathway differs by benefit type.

Alirocumab PA Requirements

Most commercial insurers and Part D plans require documentation of: a diagnosis of ASCVD or HeFH, maximum-tolerated high-intensity statin therapy, ezetimibe trial (typically 3 months or longer), and LDL-C above a threshold (commonly 70 mg/dL for ASCVD, 100 mg/dL for primary prevention) [9]. Step therapy requirements mean the PA denial rate at initial submission remains high. One 2021 analysis in JAMA Cardiology found that 56% of PCSK9 inhibitor PA requests required at least one appeal before approval [17].

Inclisiran PA Requirements

Inclisiran PA requirements at the pharmacy benefit level are largely absent because it routes through the medical benefit for physician-administered claims. Instead, payers use medical policy to control utilization, often requiring the same clinical criteria as PCSK9 antibodies (ASCVD diagnosis, statin and ezetimibe trials, documented LDL-C). Some payers have created specific medical policies for inclisiran that parallel their PCSK9 antibody PA criteria [18]. The buy-and-bill model also means the physician's office takes on inventory and reimbursement risk, which has slowed adoption at smaller cardiology practices.

Step Therapy: Statins and Ezetimibe First

The ACC/AHA 2018 Cholesterol Guideline explicitly recommends a "statin-maximized, ezetimibe-added" step before initiating PCSK9 inhibitors in most clinical scenarios [19]. Documenting this step is non-negotiable for approval of either drug. Ezetimibe 10 mg daily costs approximately $10-$20 per month as generic and lowers LDL-C by an additional 18-25% on top of statin therapy [19].

Adherence, Administration, and Patient Experience

Biweekly Self-Injection vs. Twice-Yearly Office Visit

Adherence is the most underappreciated variable in this comparison. Alirocumab requires 26 injections per year; inclisiran requires 3 in the first year and 2 in each subsequent year. A retrospective analysis of 4,963 patients initiating PCSK9 inhibitor monoclonal antibodies found 12-month medication possession ratio averaged 0.61, meaning patients were adherent to the prescribed schedule only about 61% of the time [5]. Inclisiran's in-office model theoretically shifts adherence responsibility from patient to provider.

Injection Site and Tolerability

Both drugs are administered subcutaneously in the abdomen, thigh, or upper arm. In ODYSSEY OUTCOMES, injection-site reactions occurred in 3.8% of alirocumab patients vs 2.1% placebo [6]. In ORION-10 and ORION-11, injection-site reactions occurred in 2.9% of inclisiran patients vs 1.8% placebo, predominantly mild and transient [7]. Serious adverse events were comparable to placebo in both programs.

Renal and Hepatic Considerations

Alirocumab requires no dose adjustment in mild-to-moderate renal impairment; data in severe renal impairment are limited [2]. Inclisiran is contraindicated in severe hepatic impairment (Child-Pugh C) because the GalNAc delivery system targets hepatocytes, and the pharmacokinetics in advanced liver disease are unpredictable [4]. For patients with chronic kidney disease stage 3-4 commonly seen in high-risk ASCVD populations, both drugs can generally be used, but the prescribing clinician should review renal function trends before initiating inclisiran.

Switching Between Alirocumab and Inclisiran

No pharmacokinetic washout is required when switching from alirocumab to inclisiran or vice versa, because the drugs act through different molecular compartments (extracellular vs. Intracellular). In practice, clinicians typically administer inclisiran's first dose at the next scheduled alirocumab injection interval or at any point after stopping alirocumab [10].

The HealthRX clinical team has developed the following decision framework for switching patients between agents:

Switch from alirocumab to inclisiran when:

• Patient is non-adherent to biweekly injections despite counseling
• Medicare Part B benefit makes inclisiran cost-favorable
• Patient prefers clinic-administered therapy over self-injection
• LDL-C control is adequate but administration burden is a complaint

Switch from inclisiran to alirocumab when:

• Patient loses access to a provider who can administer injections
• Insurance formulary covers alirocumab at a lower tier
• Rapid LDL-C titration is needed (alirocumab dose can be doubled from 75 mg to 150 mg mid-cycle)
• Patient has severe hepatic impairment contraindicating inclisiran

No head-to-head trial data exist to guide the switch decision on efficacy grounds. The choice is therefore largely logistical and cost-driven [10].

Who Should Get Which Drug? A Clinical Decision Guide

Very-High-Risk Post-ACS Patients

For a patient within 12 months of acute coronary syndrome who is not at LDL-C goal on maximum-intensity statin plus ezetimibe, alirocumab's ODYSSEY OUTCOMES data (15% relative MACE reduction, 1.6% absolute risk reduction) provide the most direct support [6]. The 2022 ACC/AHA chronic coronary disease guideline gives PCSK9 inhibitors with outcomes data a Class IIa, Level A recommendation in this setting [9]. Alirocumab is the evidence-first choice here.

Patients With Adherence Barriers

A patient who has missed more than 4 of the last 12 alirocumab injections, or who reports significant injection fatigue, is a strong candidate for switching to inclisiran. The twice-yearly schedule, combined with the fact that clinic staff handle administration, removes the most common adherence failure point [7].

Medicare Beneficiaries

The Part B billing pathway for inclisiran may produce lower total annual out-of-pocket costs for Medicare patients with Medigap coverage, per the 2023 Circulation modeling study [16]. Clinicians should run a benefit-level cost comparison before defaulting to alirocumab in patients over 65.

Patients With HeFH

Both drugs are approved for HeFH. Alirocumab has longer real-world use in this population and a larger body of clinical experience. A 2019 analysis of the ODYSSEY program in HeFH patients (N=735, ODYSSEY HIGH FH) showed alirocumab 150 mg every 2 weeks reduced LDL-C by 45.7% at 24 weeks vs 6.6% placebo (P<0.001) [20]. Inclisiran's ORION-9 trial (N=482) in HeFH demonstrated 39.7% mean LDL-C reduction (P<0.001) [21]. Both options are clinically reasonable; access and adherence again drive the choice.

Real-World Effectiveness and Safety Signals

Post-marketing safety data for alirocumab now span nearly a decade. The FDA FAERS database and published pharmacovigilance analyses have not identified safety signals beyond those in ODYSSEY OUTCOMES [2]. Neurocognitive concerns raised in early PCSK9 antibody development have not materialized in longer follow-up. EBBINGHAUS, a prospective substudy of FOURIER (the evolocumab outcomes trial with a similar design), found no cognitive impairment signal at 19 months with PCSK9 antibody therapy vs placebo [22].

Inclisiran's post-marketing safety database is shorter but growing. No new safety signals were identified in the first two years of U.S. Commercial use per the FDA's 2023 drug safety review update [4]. The siRNA platform is shared with givosiran and lumasiran (approved hepatic siRNAs), and that class has not produced unexpected off-target toxicity in post-marketing surveillance to date [23].

Cost-Effectiveness: What the Analyses Show

A 2021 ICER (Institute for Clinical and Economic Review) report estimated alirocumab's cost per QALY at approximately $450,000 at list price, falling to $24,000-$29,000 per QALY at the net prices negotiated by PBMs [24]. This figure places alirocumab within conventional cost-effectiveness thresholds at negotiated pricing but not at list price. Inclisiran has not yet been independently assessed for cost-effectiveness in a published ICER report as of mid-2025, partly because MACE outcomes data are still pending.

From a payer standpoint, the absence of MACE data for inclisiran complicates cost-effectiveness modeling and is one reason some insurers still restrict inclisiran to patients who have failed or are intolerant of PCSK9 antibodies.

Practical Steps to Get Either Drug Approved

1. Document diagnosis (ASCVD, HeFH, or high ASCVD risk equivalent) with ICD-10 code.
2. Record current and past statin doses with dates, including any statin intolerance documentation.
3. Confirm ezetimibe 10 mg trial of at least 90 days (or document contraindication).
4. Record current LDL-C on optimized oral therapy.
5. Submit PA with clinical notes, lab results, and medication history. Include ODYSSEY OUTCOMES citation for alirocumab PA letters; reference ACC 2022 Expert Consensus for inclisiran.
6. Appeal any denial using published guideline text. The 2022 ACC decision pathway states: "For patients with clinical ASCVD who are on maximally tolerated statin therapy with ezetimibe and have LDL-C persistently above goal, PCSK9 inhibitors are recommended" [10].
7. Enroll in manufacturer co-pay assistance programs simultaneously: Sanofi's Praluent My Support 360 for alirocumab [13] or Novartis's Leqvio CONNECT for inclisiran [15].